Targets › HCN4
3 programs from 3 companies in 3 trials: 2 Phase 3, 1 Phase 4; Cardiovascular, Infectious disease; next expected readout Dec 2026.
Hyperpolarization-activated ion channel that are permeable to Na(+) and K(+) ions with very slow activation and inactivation. Exhibits higher selectivity for K(+) over Na(+) ions. (UniProt, Q9Y3Q4)
Open in Phaseline: the race on HCN4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Second Affiliated Hospital of Guangzhou Medical University | Ivabradine Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker | HCN4 | Phase 4 | Sepsis | Dec 2026 |
| National Institute of Cardiovascular Diseases, Pakistan | Ivabradine Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker | HCN4 | Phase 3 | Cardiogenic Shock Post Myocardial Infarction | May 2027 |
| Jagiellonian University | Ivabradine Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker | HCN4 | Phase 3 | Myocardial Injury After Noncardiac Surgery (MINS) | – |
Sepsis (1) Cardiogenic Shock Post Myocardial Infarction (1) Myocardial Injury After Noncardiac Surgery (MINS) (1)
small molecule (3)
Second Affiliated Hospital of Guangzhou Medical University (1) National Institute of Cardiovascular Diseases, Pakistan (1) Jagiellonian University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.